Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.

Cancer gene therapy - 1 Jul 2023

Talbot Thomas, Lu Haonan, Aboagye Eric O

Abstract excerpt

High-grade serous ovarian carcinoma is a unique cancer characterised by universal TP53 mutations and widespread copy number alterations. These copy number alterations include deletion of tumour suppressors and amplification of driver oncogenes. Given their key oncogenic roles, amplified driver genes are often proposed as therapeutic targets. For example, development of anti-HER2 agents has been clinically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Oncogenes
Share to Ovarian Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 36804485
DOI: 10.1038/s41417-023-00589-z
PMCID: PMC9940086

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.PMID 36804485Read ↗

Critical molecular abnormalities in high-grade serous carcinoma of the ovary.Semantic proximity Read ↗

Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.Semantic proximity Read ↗

The Changing View of High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.Semantic proximity Read ↗

Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.Semantic proximity Read ↗

Integrated genomic analyses of ovarian carcinoma.Semantic proximity Read ↗

Comprehensive Genomic Characterization in Ovarian Low-Grade and Chemosensitive and Chemoresistant High-Grade Serous Carcinomas.Semantic proximity Read ↗

Genetic alterations and their therapeutic implications in epithelial ovarian cancer.Semantic proximity Read ↗

Amplicon profiles in ovarian serous carcinomas.Semantic proximity Read ↗

Ovarian cancer: emerging molecular-targeted therapiesSemantic proximity Read ↗

Genomic instability and CCNE1 amplification as emerging biomarkers for stratifying high-grade serous ovarian cancerSemantic proximity Read ↗

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.